Gates Ventures’ Kristina Malzbender Joins Alzheimer’s Moonshot Impact Board
Hope on the Horizon: A New Era of Alzheimer’s Innovation
This episode of StartUp Health NOW dives deep into the fight against Alzheimer’s disease in the second in our series of conversations with our Alzheimer’s Moonshot Impact Board. Join us as we chat with Kristina Malzbender, the Associate Director, Health & Life Sciences, at Gates Ventures. Hear from this key leader about the concrete realities behind the optimism in Alzheimer’s innovation.
- A century of relentless pursuit: Learn how the tide is turning after decades of dedicated research.
- Early detection, slowed progression, and even potential cures: Explore exciting advancements in Alzheimer’s treatment.
- Gates Ventures and the Diagnostic Accelerator (DxA): Find out how Gates Ventures and the Alzheimer’s Drug Discovery Foundation (ADDF) are supporting companies and academic researchers developing novel biomarkers and diagnostics for Alzheimer’s.
- Introducing StartUp Health’s Alzheimer’s Moonshot: Discover a powerful collaboration aimed at accelerating progress
This episode is for you if:
- You’re passionate about Alzheimer’s disease.
- You’re curious about the latest advancements in dementia research.
- You want to learn how you can contribute to the fight against Alzheimer’s.
Want even more about Alzheimer’s disease innovation?
- Learn how you can join our new Alzheimer’s Moonshot
- Meet the first companies to join the Alzheimer’s Moonshot Community.
- Meet Phyllis Ferrell, Chief Impact Officer for StartUp Health’s Alzheimer’s Moonshot
Join us as we ignite hope for the future of Alzheimer’s innovation!
Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.
Funders: Become a Health Moonshot Champion
